Les Laboratoires Servier
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Les Laboratoires Servier
The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.
In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
Market volatility, persistently high valuations, inflation and interest rates are among the issues sidetracking broader M&A, experts say.
- Generic Drugs
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Biogaran SAS
- Egis Pharmaceuticals plc
- Servier BioInnovation
- Symphogen A/S
- Servier Pharmaceuticals, LLC.